A Prospective, Single Arm, Multicenter, Real World Study to Investigate the Effectiveness and Safety of Sevikar (5/20mg) in Patients with Essential Hypertension in China (SVK study)

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026574

Enrollment

Unknown

Registered

2019-10-14

Start date

2020-11-09

Completion date

Unknown

Last updated

2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Interventions

Observation group:NA

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Essential hypertension, aged 18 to 80 years, male or female; 2. Patients planning to receive Sevikar therapy; 3. Signed the informed consent.

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

Measure	Time frame
The change in diastolic blood pressure at week 8.;	—

Secondary

Measure	Time frame
The change in systolic blood pressure at week 8;BP control rate;BP response rate to treatment;The change in home self-measured blood pressure;Patient treatment satisfaction;Physician treatment satisfaction;Treatment compliance;Vital signs;The change in laboratory and other tests;Adverse events, serious adverse events;	—

Countries

China

Contacts

Public ContactJunbo Ge

Zhongshan Hosptial, Fudan University

svk_study@outlook.com+86 21 60397260

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026